<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734536</url>
  </required_header>
  <id_info>
    <org_study_id>REGEN.PUB.2018.09</org_study_id>
    <nct_id>NCT03734536</nct_id>
  </id_info>
  <brief_title>Treatment of Partial-Thickness Rotator Cuff Tears</brief_title>
  <acronym>REGEN PUB 2018</acronym>
  <official_title>Prospective Multi-center Study Comparing REGENETEN in Lieu of Standard Arthroscopic Repair of High-grade (&gt;50%) Partial-thickness Tears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Research Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Metrics Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate that REGENETEN is superior to standard repair techniques when surgically treating
      high-grade (&gt;50%) partial-thickness tears because REGENETEN preserves more of the native
      tendon footprint resulting in less postoperative pain and faster recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate arthroscopic surgical treatment of high-grade
      (&gt;50%) partial-thickness tears using REGENETEN yields statistically superior patient
      post-operative recovery outcomes, faster return to activities of daily living, and less
      health care utilization versus standard surgical repair techniques.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">July 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ASES (American Shoulder and Elbow Surgeons) score tear using standard surgical techniques.</measure>
    <time_frame>at 3 months following index surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASES score</measure>
    <time_frame>over initial 3 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Assessment Numeric Value (SANE) score</measure>
    <time_frame>over initial 3 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASES Visual Analog Scale (VAS) pain score</measure>
    <time_frame>over initial 3 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASES score</measure>
    <time_frame>at 6, 12, 18 and 24 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SANE score</measure>
    <time_frame>at 6, 12, 18 and 24 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASES VAS pain score</measure>
    <time_frame>at 6, 12, 18 and 24 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder Stiffness Visual Analog Scale (VAS) score</measure>
    <time_frame>over 12 months following index surgery</time_frame>
    <description>Stiffness in the participant's index shoulder will be assessed using the shoulder stiffness VAS. The VAS is a continuous scale comprised of a horizontal line 100 millimeters (mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme: No Stiffness (0 mm) and Extreme Stiffness (100 mm). The VAS stiffness rating will be recorded pre-operatively, weekly from 1 week to 3 months post-surgery, and at 6 and 12 months post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative opioid use to treat the index shoulder</measure>
    <time_frame>over 12 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative non-opioid prescription medication use to treat the index shoulder</measure>
    <time_frame>over 12 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of shoulder immobilization</measure>
    <time_frame>following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to activities of daily living (ADLs) o Return to work by work type (sedentary; laborer) o Return to driving o Return to sports</measure>
    <time_frame>following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression to full-thickness tear</measure>
    <time_frame>within 12 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression to full-thickness tear</measure>
    <time_frame>within 24 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of revision surgery (index shoulder; all causes)</measure>
    <time_frame>within 24 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregate health care utilization costs</measure>
    <time_frame>over 12 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operating room time (index surgery)</measure>
    <time_frame>Intra-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of steroid injections</measure>
    <time_frame>over 12 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unscheduled clinic visits</measure>
    <time_frame>over 12 months following index surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of for-cause imaging procedures</measure>
    <time_frame>over 12 months following index surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Arthroscopic Surgical Treatment of High-grade (&gt;50%) Partialthickness</condition>
  <arm_group>
    <arm_group_label>REGENETEN™ Bioinductive Implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arthroscopic repair of the high-grade (&gt;50%) partialthickness</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical treatment of partial-thickness rotator cuff tears using standard techniques.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REGENETEN™ Bioinductive Implant</intervention_name>
    <description>The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.</description>
    <arm_group_label>REGENETEN™ Bioinductive Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arthroscopic repair of the high-grade (&gt;50%) partialthickness</intervention_name>
    <description>Surgical treatment of partial-thickness rotator cuff tears using standard techniques.</description>
    <arm_group_label>Arthroscopic repair of the high-grade (&gt;50%) partialthickness</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be considered qualified for enrollment if they meet the following criteria:

          1. Male or female ≥18 years

          2. High-grade (&gt;50% tendon thickness) partial-thickness tear

          3. Failed conservative medical management of the tendon tear defined as:

               1. Four (4) to six (6) weeks of formal physical therapy or guided home exercises

               2. Activity modification

               3. Shoulder injection at the discretion of the surgeon

          4. Able to comply with the post-operative physiotherapy and follow-up schedule

          5. Able to speak and read English Provide written informed consent

        Exclusion Criteria:

        Any one (1) of the following criteria will disqualify a patient from participation in the
        study:

          1. Prior shoulder surgery on index shoulder within 12 months of enrollment

          2. Failed primary rotator cuff surgery of the index shoulder

          3. On steroids within 1 month of enrollment

          4. Metastatic disease

          5. Concomitant surgeries for bone defects requiring bone implantation (Latarjet
             procedures) or for superior labral tear from anterior to posterior (SLAP)

          6. Concomitant biceps tenodesis

          7. Rheumatoid arthritis

          8. Advanced osteoarthritis

          9. Fatty infiltration of the index shoulder rotator cuff muscle ≥ Grade 3

         10. Chronic pain disorders (i.e., fibromyalgia)

         11. History of insulin dependent diabetes

         12. History of heavy smoking (&gt; 1 pack per day) within 6 months of enrollment

         13. Currently involved in any injury litigation or workers compensation claims

         14. Hypersensitivity to bovine-derived materials Medical or physical condition that, in
             the opinion of the Investigator, would preclude safe participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristin Taylor</last_name>
    <role>Study Chair</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karlie Morgan</last_name>
    <phone>512-496-7507</phone>
    <email>Karlie.morgan@smith-nephew.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristin Taylor</last_name>
    <phone>978-289-3388</phone>
    <email>Cristin.Taylor@smith-nephew.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida Orthopaedics and Sports Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Bruner</last_name>
      <phone>352-273-7337</phone>
      <email>bruneml@ortho.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Farmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Dubin</last_name>
      <email>Marcia.Dubin@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Kamal Bohsali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Clinic</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Brannon</last_name>
      <phone>762-235-3889</phone>
      <email>TBrannon@HarbinClinic.com</email>
    </contact>
    <investigator>
      <last_name>Brad Bushnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cale Jacobs</last_name>
      <phone>859-797-8197</phone>
      <email>cale.jacobs@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Mair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Maggio</last_name>
      <email>jmaggio@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Deryk Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brook Fowler</last_name>
      <phone>443-481-5757</phone>
      <email>mfowler3@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Dan Redziniak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Syracuse Orthopedic Specialist</name>
      <address>
        <city>DeWitt</city>
        <state>New York</state>
        <zip>13214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Maddocks</last_name>
      <phone>315-251-3276</phone>
      <email>Corinne.Maddocks@sosbones.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Raphael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Orthopedic Specialists</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Morgan</last_name>
      <phone>817-510-4022</phone>
      <email>amber@txortho.net</email>
    </contact>
    <investigator>
      <last_name>Howard Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>REGENETEN</keyword>
  <keyword>REGENETEN Bioinductive Implant</keyword>
  <keyword>highgrade partial thickness tear</keyword>
  <keyword>rotator cuff tear</keyword>
  <keyword>rotator cuff repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

